Wednesday, January 25, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

DHS Assesses Tetracore’s Anthrax Lateral Flow Assay

by Global Biodefense Staff
October 20, 2016
Tetracore Anthrax Lateral Flow Assay

Tetracore Anthrax Lateral Flow AssayTetracore Inc. this week announced the successful completion of an extensive study of its Anthrax BioThreat Alert Lateral Flow Assay (LFA) and the BioThreat Alert Reader by the Department of Homeland Security (DHS).

Public safety and health concerns lead DHS to perform a comprehensive laboratory validation study of a commercially available LFA for the rapid detection of B. anthracis. When suspect environmental samples, including unknown white powders, are discovered in the field, authorities are tasked to determine if B. anthracis or another biological threat agent is present.

The goal of this study was to provide a reliable rapid field test for anthrax spores, to enable better informed decisions by first responders and public health officials to increase public safety and reduce the economic impact of false alarms.

The study concludes that with an overall sensitivity and specificity of more than 98%, it is a rapid and dependable test supporting its use in the field and laboratory for the purpose of qualitatively evaluating suspect samples for the presumptive presence of anthrax spores.

The study was designed and executed by DHS Program Manager Dr. David Hodge of the DHS S&T Chemical and Biological Defense Division, and then DHS Science Advisor Dr. Segaran Pillai through an interagency collaboration with DHS S&T, DHS CRSO, HHS ASPR/BARDA, HHS CDC, DOJ FBI, USSS, FDA CDRH, FDA CFSAN, USDA ARS, CSU-Fresno, LLNL and LBNL.

Tetracore’s Anthrax BioThreat Alert Test and BioThreat Alert Reader were evaluated at two different testing locations: Zoonoses and Select Agent Laboratory, Bacterial Special Pathogens Branch, National Center for Emerging and Zoonotic Infectious Diseases, CDC, Atlanta, GA, and Omni Array Biotechnology, Rockville, MD.

The study consisted of six phases that include limit of detection and repeatability, ability to detect inclusivity panel, near-neighbor panel, environmental background panel microbes, white powder panel and environmental filter extract to thoroughly test LFA performance.  The panels utilized in this validation were extensive and provided a robust process to assess the performance of the assay.  No other commercial LFA developed for field screening of B. anthracis has been comprehensively and independently validated until now.

“Tetracore respects our on-going collaboration with DHS and will continue to validate our BioThreat Alert LFA products rigorously, so that public health laboratories and first responders have confidence in screening for biological threats,” stated Dr. Tom O’Brien, Vice President of Tetracore Inc.

Read more at Health Security: Comprehensive Laboratory Evaluation of a Highly Specific Lateral Flow Assay for the Presumptive Identification of Bacillus anthracis Spores in Suspicious White Powders and Environmental Samples.

Tags: AnthraxASPRHHSMobile ResponsePOC Diagnostics

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development
Industry News

DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development

January 10, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC